Background

For individuals living with the dual burden of chronic migraine (CM) and medication-overuse headache (MOH), finding an effective treatment path can feel like a moving target.

The primary results of the international RESOLUTION trial, recently published in Neurology, offer definitive clinical evidence that combining a fast-acting preventive treatment with simple patient education can drastically reduce headache frequency and successfully break the cycle of acute medication overuse.

The RESOLUTION trial was designed to tackle a major challenge in headache medicine: managing patients who suffer from chronic migraine while simultaneously overusing acute pain medications. Frequent use of acute treatments often leads to rebound headaches, trapping patients in a vicious cycle. This phase 4 study evaluated whether this intravenous IV treatment breaks severe migraine and medication-overuse cycles when paired with behavioral guidance.

How the Study Was Done

The 12-week, randomized, placebo-controlled trial evaluated 604 treated adult patients across 11 countries. Every participant in the study entered with a highly severe headache profile:

• High Baseline Burden: Patients averaged 20.9 monthly migraine days and used acute pain medications on 20.1 days per month.
• Prior Treatment Failures: 44% of participants had already tried and failed two or more prior preventive migraine medications.

All patients in the study received a Brief Educational Intervention (BEI)—a focused, 10-minute session explaining the link between frequent acute drug use and rebound headaches, alongside a plan to taper or stop overused acute medications. Patients were then randomized to receive either a single intravenous infusion of eptinezumab (100 mg) or a placebo.

Study Results

The trial met all primary and secondary endpoints with high statistical significance, demonstrating that the addition of eptinezumab delivered rapid and sustained relief over the 12-week period.

• Rapid Reduction in Migraine Days: During the first month alone (Weeks 1–4), patients treated with eptinezumab saw their monthly migraine days drop by an average of 6.9 days, compared to a 3.7-day reduction in the placebo group. By the end of the 12-week study, the eptinezumab group achieved an overall reduction of 7.4 monthly migraine days.
• Dropping the Rebound Medications: Eptinezumab allowed patients to safely and significantly step away from daily acute pain relievers. During weeks 1–4, patients in the active group reduced their acute medication use by 11.3 days, compared to 7.7 days in the placebo group.
• Achieving Diagnostic Remission: Within the first month, 37.8% of patients in the eptinezumab group achieved full diagnostic remission—meaning they no longer met the criteria for either chronic migraine or medication-overuse headache. This represents a 3.3 times higher odds of remission compared to behavioral education alone.
• Safety and Tolerability: The study confirmed that eptinezumab is highly tolerable, with a safety profile nearly identical to the placebo group:
  • Common Events: The most frequent side effects were mild, including nasopharyngitis (5.0%), influenza, and fatigue.
  • Low Discontinuation: Side effects were rarely a reason to stop treatment; only 0.3% of patients receiving eptinezumab discontinued the study due to an adverse event, compared to 1.0% in the placebo group.

Conclusion

The primary results published in Neurology demonstrate that combining eptinezumab with brief educational insights provides a powerful, fast-acting solution for patients caught in the chronic migraine and medication-overuse cycle. By significantly reducing migraine days and acute medication dependency within the first month, this approach offers a clear, manageable pathway toward diagnostic remission.

Explore More From the RESOLUTION Trial

Want to know how this treatment affects workplace productivity, focus, and daily functioning? Read our summary of the Cephalalgia publication on Patient-Reported Outcomes and Quality of Life.

Curious about what happens after the initial 12 weeks? Read our breakdown of the Journal of Headache and Pain publication, covering the 24-week long-term safety and extension data.